Overcoming Development Challenges for ADCs and AOCs
Antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) deliver potent payloads, like cytotoxic drugs or gene-modulating oligonucleotides, to treat cancer, neuromuscular, and metabolic diseases. Clinical success depends on multiple factors, including linker stability, controlled intracellular payload release, minimal off-target toxicity, and consistent efficacy across varying levels or target antigen expression. However, conventional preclinical models often fail to accurately recapitulate human target biology, limiting their translational relevance and predictive value. For AOCs, additional challenges include maintaining oligonucleotide integrity and biological activity following conjugation, as well as achieving effective intracellular delivery to the intended site of action.
Cyagen addresses the key challenges of ADC and AOC development hurdles through a fully integrated discovery and preclinical evaluation platform. Our fully human antibody discovery mice generate high-affinity, fully human antibodies well suited for conjugation and tarheted delivery applications. For in vitro validation, our cell model services provide robust assays to assess target binding, cellular internalization, cytotoxic activity, payload delivery, and gene-silencing efficacy. To improve translational relevance, we develop custom humanized mouse models expressing human target antigens, enabling more predictive in vivo evaluation of therapeutic candidates. Complementing these capabilities, Cyagen’s expert preclinical CRO team designs and executes tailored studies spanning biodistribution, efficacy, PK/PD, and safety assessments. Together, these integrated solutions generate high-quality data that support informed candidate selection, reduce development risk, and accelerate progression toward clinical and regulatory milestones.
Antibody-Drug Conjugates (ADCs)
Antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) are targeted therapeutics that combine the specificity of monoclonal antibodies with potent payloads through specialized chemical linkers. In ADCs, the payload is typically a cytotoxic agent designed to eliminate diseased cells, while in AOCs, it consist of a therapeutic oligonucleotides that modulate gene expression. By binding to specific antigens on target cells, these conjugates facilitate selective intracellular delivery of their payloads, enhancing therapeutic efficacy while minimizing exposure and toxicity to healthy tissues.
The therapeutic performance of any ADC or AOC heavily depends on the quality of its antibody component. An ideal antibody candidate must combine high target specificity and affinity with efficient cellular internalization, optimal conjugation properties, favorable pharmacokinetics, and low immunogenicity. Together, these properties enable precise payload delivery while reducing off-target toxicity.
Fully human monoclonal antibodies and nanobodies offer distinct advantages over traditional chimeric or murine formats, including lower immunogenicity, improved safety profiles, and enhanced developability. As a result, the selection of high-quality antibody is one of the most important factors influencing the efficaciy, safety, and clinical potential of ADC and AOC therapeutics. .
How Cyagen’s HUGO-Ab™ Platform Supports Your Antibody Discovery
Cyagen offers a comprehensive portfolio of humanized mouse models, including multiplex humanized systems, designed to meet the rigorous in vivo evaluation requirements for ADCs and AOCs therapeutics.
Built on our HUGO-GT™ gene-targeting platform, these models precisely replace endogenous mouse genes with human counterparts, enabling physiologically relevant expression of therapeutic targets. This approach supports more predictive in vivo assessment of target binding, biodistribution, efficacy, PK/PD, and safety, generating data with greater translational relevance to clinical outcomes.
For next-generation therapeutics, Cyagen’s multiplex humanized models provide additional flexibility by co-humanizing multiple interacting genes within a single animal. These models enable evaluation of bispecific ADCs and AOCs, dual-targeting strategies, immuno-oncology combinations, and other complex therapeutic modalities that require a simultaneous integration of multiple human pathways. By recreating key human biological interactions in vivo, multiplex models offer a powerful platform for studying therapeutic mechanisms and optimizing candidate selection.
Whether your program requires single-target humanized models, multiplex humanized systems, or fully integrated CRO support for efficacy, PK/PD, biodistribution, and safety studies, Cyagen provides the human-relevant models and scientific expertise to accelerate your ADC and AOC development with greater confidence and translational predicatbility.
| Catalog Number | Name | Base Strain | Research Application | Action |
|---|---|---|---|---|
| {{ value.product_num || "--" }} | {{ value.product_name || "--" }} | {{ value.product_strain || "--" }} |
；
|
+
|
Case Study
- {{v2}}
- {{item}}
